Key Points
- What it is: Azaprocin is a laboratory-made opioid in the acyl piperazine family. It is not a kratom extract, a dietary supplement, or an FDA-approved pain medication.
- Potency: A study in rodents found azaprocin approximately five times as potent as morphine in a particular pain-response experiment. That finding cannot be translated into a safe or equivalent human dose.
- What is known about availability: A 2024 UK scientific review found no reported detections of azaprocin itself in Europe or North America at the time. That is different from related acyl piperazine opioids, which have been detected in the illicit drug supply.
- Primary risk: Its opioid receptor activity raises concerns about dangerous sedation, slowed breathing, overdose, and dependence, although direct human data on azaprocin are extremely limited.
- Overdose response: If someone is unresponsive or breathing abnormally after possible opioid exposure, administer naloxone if available and call 911. Do not wait to identify the substance.
- How Brooks Helps: Brooks Healing Center offers medically supervised detox, residential care, and individualized medication-assisted treatment for opioid-related problems, including assessment for FDA-approved buprenorphine options.
You may have come across the name azaprocyn while looking into synthetic opioids, research chemicals, or substances described as alternatives to more familiar drugs. The name used in scientific records is actually azaprocin. It is a real opioid compound, but much of what people might assume about its use, strength, or presence on the street has not been established in humans.
That distinction matters. We have seen how quickly unfamiliar opioid names can circulate online, especially when they get grouped with fentanyl, nitazenes, or newer products marketed to people looking for something different from 7-OH. Azaprocin deserves attention because of its pharmacology, but it also deserves an honest explanation of what researchers know and what they do not.
What Is Azaprocin?
Azaprocin is a synthetic opioid analgesic compound originally studied decades ago as part of efforts to develop pain-relieving drugs. It belongs to the acyl piperazine family, a group that also includes AP-237 (bucinnazine), 2-methyl-AP-237, and AP-238. More specifically, azaprocin has a bridged chemical structure that distinguishes it from several of those related compounds.
Like morphine and fentanyl, azaprocin activates the brain’s mu-opioid receptors. Those receptors are involved in pain relief, reward, and the suppression of breathing. Activating them can produce analgesic effects, but strong opioid activity also creates the potential for serious harm when a drug is used outside a carefully studied medical setting.
The U.S. Food and Drug Administration’s substance registry lists azaprocin by name. However, being assigned an ingredient identifier is not FDA approval, and azaprocin is not an FDA-approved treatment for pain, withdrawal, or opioid use disorder.
How Strong Is Azaprocin Compared With Morphine?
This is where the available evidence needs some context. In its 2024 report on acyl piperazine opioids, the United Kingdom’s Advisory Council on the Misuse of Drugs (ACMD) summarized an animal experiment in which azaprocin was about five times as potent as morphine when the drugs were administered intraperitoneally to rodents. The related compound para-nitroazaprocin was approximately 15 times as potent as morphine in that same comparison.
Those figures describe a particular animal test, not what would happen to a person taking an unknown product. Potency varies with the test being performed, route of exposure, and other factors. There are not adequate human studies to calculate an azaprocin-to-morphine conversion, recommend a dose, or establish that one amount will reliably produce a certain effect.
It would also be misleading to call azaprocin “stronger than fentanyl” based on this evidence. The scientific record does not support a reliable head-to-head human comparison. What it does establish is that azaprocin has meaningful opioid activity and should not be treated as a harmless experimental substance.
Azaprocin vs. AP-237, 2-Methyl-AP-237, and Other Emerging Opioids
The names are similar enough that they can easily be confused, but they do not refer to the same chemical. There is also a big difference between a substance studied in a laboratory and one actually identified in toxicology reports or seized products.
| Substance | What the evidence shows | Important distinction |
|---|---|---|
| Azaprocin | A potent mu-opioid receptor agonist studied largely in laboratory and animal research | The ACMD reported no known European or North American detections in its 2024 review |
| Para-nitroazaprocin | A chemically related compound with strong effects in rodent studies | Human exposure and safety information are similarly limited |
| AP-237 (bucinnazine) | A related acyl piperazine opioid identified in seized material; it has also had limited medical use for pain in China | Its history does not mean azaprocin is an approved medicine |
| 2-Methyl-AP-237 | A related synthetic opioid detected in illicit drug markets and associated with reported overdoses and deaths | Documented harms involving this compound should not be incorrectly attributed to azaprocin |
| Nitazenes | A different chemical family of potent synthetic opioids associated with serious overdoses | Similar opioid effects do not make nitazenes and azaprocin the same drug |
Brooks has also covered nitazenes and their overdose risks. It is useful to understand these categories separately, particularly because a name on a package or online listing cannot establish what a product actually contains.
Is Azaprocin Showing Up in the United States?
There is not enough verified evidence to describe azaprocin as a widespread or confirmed new U.S. street-drug trend. When the ACMD published its review in March 2024, it specifically reported no information about detections of azaprocin in either North America or Europe. The same report documented seizures and overdose cases involving other members of the acyl piperazine family, including 2-methyl-AP-237.
That 2024 finding is a snapshot, not a guarantee that azaprocin could never appear in an unregulated product. Unfamiliar synthetic opioids can be difficult to identify without specialized laboratory methods, and drug markets change. Still, a sensible public-health article should not turn a theoretical risk into claims of confirmed local overdoses without evidence.
The United Kingdom classified azaprocin and five related compounds as Class A controlled drugs under legislation that took effect in January 2025. The decision reflected concern about the opioid activity and potential harms of this chemical family; it was not proof that azaprocin had become common in the United States.
What Are the Possible Side Effects and Overdose Risks?
Because azaprocin activates mu-opioid receptors, scientists are concerned about effects associated with other strong opioids. The ACMD identified respiratory depression, meaning slowed or inadequate breathing, as the most serious anticipated acute harm from the acyl piperazine group. Severe respiratory depression can progress to respiratory arrest and death.
Possible opioid-related warning signs include unusually heavy sedation, impaired alertness, nausea, and very slow or shallow breathing. People who combine opioids with alcohol, benzodiazepines, or other sedating substances face additional danger. For azaprocin specifically, researchers have not established the frequency of these effects in humans, so they should be described as expected opioid-class risks rather than a proven list of clinical effects.
If you think someone is overdosing, look for:
- An inability to wake the person or get a meaningful response
- Slow, shallow, irregular, or absent breathing
- Gurgling, choking, or snoring-like sounds from someone who cannot be awakened
- Blue, gray, or unusually pale lips or fingernails
- Very small pupils, although pupil size alone cannot confirm or exclude an overdose
Call 911 immediately and give naloxone if it is available. Follow the product instructions, support breathing as directed by emergency dispatch, and stay with the person until responders arrive. The CDC recommends administering another naloxone dose if normal breathing has not returned after two to three minutes. Naloxone is an emergency measure, not a replacement for medical evaluation.
Can Naloxone Reverse an Azaprocin Overdose?
Naloxone is designed to block opioid receptor activity, which makes it appropriate to administer during a suspected opioid overdose. In laboratory research summarized by the ACMD, naloxone reversed azaprocin’s pain-relieving effect in animals. The same review described improvement after naloxone in some human overdoses involving other acyl piperazine compounds.
That does not mean an azaprocin-specific human overdose response has been established. If the substance is unknown, do not spend time trying to determine which opioid was taken before giving naloxone and calling for emergency help. Additional doses and professional airway support may be needed.
Can Azaprocin Cause Addiction or Withdrawal?
There are not controlled human studies that tell us how quickly azaprocin produces tolerance, dependence, or withdrawal, or how long an azaprocin-specific withdrawal syndrome might last. What researchers do know is that azaprocin activates the receptor system responsible for dependence with many other opioids. The ACMD therefore considers addiction and dependence credible risks for the broader drug family.
Someone using a product sold as azaprocin, another research opioid, or an unknown opioid blend should not assume withdrawal will be mild just because the name is unfamiliar. Symptoms following repeated opioid exposure may include anxiety, sweating, stomach upset, diarrhea, muscle aches, difficulty sleeping, and intense cravings. The right response is an individualized medical assessment, not an improvised taper based on an online potency claim.
It is also important to distinguish physical dependence from opioid use disorder. A person can become physically dependent on an opioid without meeting the clinical criteria for addiction, although continued use despite harm, loss of control, and repeated unsuccessful attempts to stop are reasons to seek help.
Is Azaprocin a Kratom or 7-OH Alternative?
Azaprocin is not derived from kratom. Unlike 7-hydroxymitragynine (7-OH) or mitragynine pseudoindoxyl, it belongs to a separate synthetic opioid family. What these drugs have in common is activity at opioid receptors, not botanical origin or proven interchangeability.
That distinction matters when products are promoted as substitutes for opioids, kratom extracts, or medications used in recovery. There is no clinical evidence supporting azaprocin as a safer replacement or a method for treating opioid withdrawal. If you have been reading about these substitutes, our discussion of pseudoindoxyl versus 7-OH explains why changes in chemical names do not eliminate dependence and overdose concerns.
Treatment for Synthetic Opioid Dependence in Tennessee
If opioid use has started affecting your breathing, sleep, work, relationships, or ability to stop, you do not have to identify the exact chemical before asking for help. A treatment team can evaluate your symptoms, substance-use history, and immediate safety needs. Clinical decisions should be based on the individual rather than an unverified online label.
At Brooks Healing Center, medical detox in Tennessee provides supervised stabilization and withdrawal management. Depending on the assessment, clients may continue into residential treatment and structured recovery support that addresses more than the immediate physical symptoms.
For people with opioid use disorder, medication-assisted treatment (MAT) can be part of a comprehensive plan. Brooks uses FDA-approved medications when clinically appropriate, including buprenorphine options such as Sublocade and Brixadi. Azaprocin is not an approved MAT medication and is not offered as treatment.
Our center is located between Nashville and Chattanooga in Normandy, Tennessee, and we help adults and families from across Middle Tennessee understand the next step. To talk with admissions about opioid treatment, call 931-486-8824 or learn more about Brooks’ opioid addiction treatment services.
Frequently Asked Questions About Azaprocin
Is azaprocyn the same thing as azaprocin?
Azaprocin is the documented chemical name listed in the FDA’s substance registry and scientific reviews. “Azaprocyn” appears to be a spelling variation or misspelling, not a separate, established opioid compound. If a product uses either spelling, that label alone does not verify its contents.
Is azaprocin stronger than morphine?
One rodent experiment found azaprocin approximately five times as potent as morphine under specified experimental conditions. This result cannot be used to estimate a safe dose or an equivalent amount for humans. There are no adequate human potency studies to support that calculation.
Is azaprocin fentanyl?
No. Both are synthetic opioids that activate mu-opioid receptors, but they are chemically different drugs. Azaprocin belongs to the acyl piperazine family, while fentanyl belongs to another chemical class.
Is azaprocin FDA-approved?
No. Its appearance in an FDA chemical-identity registry is not evidence of drug approval. Azaprocin is not an FDA-approved medication for pain management, opioid withdrawal, or addiction treatment.
Will azaprocin show up on a standard drug test?
Routine drug screens do not reliably identify every newer or uncommon synthetic opioid. Identifying an unusual compound may require specialized laboratory testing, and whether azaprocin can be identified depends on the specific test and its validated targets. If someone has symptoms of an opioid overdose, treatment should never wait for a test result.
How long does azaprocin stay in your system?
There is no reliable, clinically validated human detection window or half-life for azaprocin. Claims that it remains detectable for a precise number of hours or days should be treated cautiously unless supported by testing specific to this compound.
References
Advisory Council on the Misuse of Drugs. (2024, March 27). Acyl piperazine opioids, including 2-methyl-AP-237. UK Home Office. https://www.gov.uk/government/publications/acmd-advice-on-acyl-piperazine-opioids-including-2-methyl-ap-237/acmd-advice-on-acyl-piperazine-opioids-including-2-methyl-ap-237-accessible
Centers for Disease Control and Prevention. (2024, May 2). 5 things to know about naloxone. https://www.cdc.gov/overdose-prevention/reversing-overdose/about-naloxone.html
Cignarella, G., Barlocco, D., Tranquillini, M. E., Volterra, A., Brunello, N., & Racagni, G. (1988). Interaction of 3,8-diazabicyclo(3.2.1)octanes with μ and δ opioid receptors. Pharmacological Research Communications, 20(5), 383–394. https://doi.org/10.1016/S0031-6989(88)80014-6
Home Office. (2025, January 15). The Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2024 and the Misuse of Drugs and Misuse of Drugs (Designation) (England and Wales and Scotland) (Amendment) (No. 2) Regulations 2024. GOV.UK. https://www.gov.uk/government/publications/circular-0022025-the-misuse-of-drugs-act-1971-order-2024/the-misuse-of-drugs-act-1971-amendment-no-2-order-2024-and-the-misuse-of-drugs-and-misuse-of-drugs-designation-england-and-wales-and-scotland
Substance Abuse and Mental Health Services Administration. (2026, April 24). Updated guidance on medication-assisted treatment/medications for opioid use disorder. https://www.samhsa.gov/sites/default/files/dear-colleague-letter-mat-moud-guidance.pdf
U.S. Food and Drug Administration. (n.d.). Azaprocin (UNII D20F1K1BYP). UNII Search Service. Retrieved November 5, 2026, from https://precision.fda.gov/uniisearch/srs/unii/D20F1K1BYP
